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Abstract 
Chronic Hepatitis B infection can lead to significant 
morbidity and mortality. Case notes of patients who tested 
positive for HBsAg between 1st Dec 2007 and 29th 
October 2009 were reviewed (n=197) . The results show 
that 2/3 (65%) of the study population were male and that 
HBV infection was detected across all age groups. About 
¼ (25.4%) of the study group were foreigners. 79% of 
Maltese patients testing postive did not have any 
identifiable risk factors documented in their case notes for 
acquiring HBV. In more than 60% of patients who tested 
positive further assessment to determine suitability for 
treatment was not performed and only 6.6 % of the study 
population received treatment for HBV. 
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Introduction 
Hepatitis B (HBV) is a DNA virus which belongs 
to the family of hepadnaviruses .After exposure to the 
virus the patient develops an acute infection which 
may or may not progress to a chronic hepatitis. Acute 
Hepatitis B infection is subclinical in 70% of infected 
patients while the rest develop jaundice. A small 
minority (0.1-0.5%) of acutely infected patients 
develop fulminant hepatic failure
1
  which is  life 
threatening. Chronic HBV hepatitis (CHB) is often 
silent for many years, however, it can lead to cirrhosis 
in 8-20% of patients within 5 years of diagnosis
2
. 
About one fifth of HBV cirrhotics will go on to 
develop liver failure in 5 years time and would have a 
poor prognosis unless transplanted.CHB also 
predisposes the patient to develop hepatocellular 
carcinoma (2-5% per annum).
2
 
Worldwide, two billion people have serological 
evidence of past or present infection with HBV, 
whereas more than 350 million people are chronically 
infected. Globally HBV cirrhosis and hepatocellular 
carcinoma cause more than 1 million deaths per year 
and account for approximately 5-10 % of liver 
transplants in the developed world.
3,4,5
   
In developed countries the prevalence of chronic 
infection (HBsAg prevalence)  is about 2%. In these 
low prevalence areas the main modes of transmission 
are through sharing of contaminated needles amongst 
intravenous drug abusers and unprotected sexual 
intercourse. Although rare, some individuals acquire 
the infection iatrogenically when there is non-
compliance with infection control practices. Infection 
in these areas is often acquired in adulthood and only 
10% of those infected go on to develop chronic HBV 
hepatitis. 
On the other hand in areas of high prevalence 
(8%) such as SE Asia , Sub-Saharan Africa and the 
Amazon basin, the infection is often aquired 
perinatally or in early childhood either through vertical 
transmission (mother to child) or through the use of 
non-disposable medical equipment. The majority 
(90%) of individuals who are exposed at a young age 
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develop chronic HBV hepatitis with its associated risks of 
cirrhosis and hepatocellular carcinoma.
3
  
Reduction in HBV transmission is best achieved 
through vaccination programs prior to infection. The 
world’s first nationwide universal vaccination program for 
HBV vaccination was launched in 1984 in Asia (Taiwan).
7
  
The vaccine is 95% effective in preventing the 
development of chronic infection. In 1991, the World 
Health Organization (WHO) recommended adding HBV 
vaccination to all national immunization programs.
3
 In 
Malta universal HBV vaccination is recommended at 15 
months of age.
10 
 
Patients with acute severe hepatitis are candidates for 
treatment as this can reduce the need for liver 
transplantation.
11
 In patients with chronic hepatitis, 
avoiding the development of cirrhosis and hepatocellular 
carcinoma leads to improved survival and this is best 
achieved through a sustained and profound suppression of 
HBV replication.
6 
Treatment in these patients is 
recommended if there is evidence of active viral 
replication as well as ongoing liver injury. Ongoing liver 
injury is evidenced by raised liver transaminases 
(ALT/AST)  as well as fibrosis and inflammation on liver 
biopsy.
6,8
 Active viral replication is evidenced by detecting 
HBV DNA in the patient’s blood. Chronic HBV infection 
is an evolving process passing through various phases 
depending on how the virus and the host immune system 
interact (Table 1). According to the EASL guidelines the 
chronically infected patients who require treatment are 
those in the  Immune Reactive Phase as well as the HBeAg 
negative HBV DNA positive chronic HBV hepatitis (Pre-
core mutation) patients.
6
 All patients with chronic HBV 
however, should be followed up by a gastroenterologist or 
an infectious disease specialist even when there are 
undetectable HBV DNA levels as these patients can still 
develop complications later on in life. 
 
 
Disease 
Phase 
HBsAg HBeAg HBV 
DNA 
Liver 
Injury 
Treatment 
required 
Immune 
tolerant 
+ + + No No 
Immune 
reactive 
+ + + Yes Yes 
Inactive 
HBV 
carrier 
+ - - No No 
HBeAg 
Neg CHB 
(precore 
mutation) 
+ - + Yes Yes 
HBsAg 
Negative  
- - - No No 
Table: 1 The various phases of chronic HBV infection. 
 
 
Two classes of drugs are used to treat chronic 
HBV infection, namely nucleoside/nucleotide 
analogues (NUCS) and Interferon-alpha. The precise 
way Interferon-alpha works is not known. It is released 
by infected cells as well as activated lymphoctes and is 
able to kill infected cells through protein sythesis 
inhibition and immune mechanisms. It can also protect  
uninfected cells from viral takeover.
9
 NUCS are 
incorporated into growing viral DNA strands but act as 
chain terminators hence inhibiting HBV replication.
12
  
 
 
Aims of study 
1. To characterise Hepatitis B infection in Malta. 
2. To audit the clinical evaluation and management 
of HBsAg positive patients in Malta. 
 
 
Methods 
This study was carried out by reviewing case notes 
of those patients who tested positive to HbsAg or HBV 
DNA in Malta between 1
st
 December 2007 and 29
th
 
October 2009. This data was derived from the 
Virology Dept at Mater Dei Hospital. A number 
(n=29) of HBsAg positive results could not be 
assessed furthur as their identification was coded. The 
list of patients studied was further amplified by 
identifying any patients who also tested positive for 
Hepatitis B through routine screening of blood donors 
as well as at the Detox and Genitourinary clinics. Prior 
to retrieving case files, approval by the Director Data 
Protection as well as chairpersons of the various 
clinical departments at Mater Dei was obtained. A 
total of 197 files were analysed looking at the 
demographic data, the stage of the disease as well as 
auditing the investigation and management of these 
cases. For the purposes of the audit, management was 
compared with the EASL practice guidelines 
published in 2009.
6
 
 
 
Results 
Demographic data (Figures 1and 2)  
Approximately 2/3 of the infected individuals 
were males. About ¾ (74.6%) of the study population 
were Maltese whereas the rest (50 cases) were 
foreigners. Infection was detected in all age groups 
including young individuals suggesting that 
transmission of HBV is still ongoing. 
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Figure 1: Gender distribution in study population 
 
 
Figure 2: Age distribution in study population 
 
 
Risk factors for transmission  
A minority of cases were documented to have tattoos 
(1%), perinatal transmission (1%), and intravenous drug 
use (3.5%), history of previous blood transfusion (3.5%) or 
sexual promiscuity (3.5%). In 2% of the cases, familial 
clustering was documented. However more importantly in 
79% of Maltese cases there was no identifiable risk factor 
for HBV transmission documented in the case notes. This 
implies either reluctance of patients to admit to high risk 
behaviour or less likely the possibility that iatrogenic 
transmission is commoner than we think. 
 
 
Further assessment following diagnosis of HBsAg 
positivity (Figure 3) 
Once someone is found to be HbsAg positive it is 
important that further tests are done (HBV DNA ,HbeAg, 
Anti HBeAb) so that the phase of the disease is determined. 
Our  results show that in many patients (41%) these tests 
were not done and therefore it was not possible to classify  
the phase of the disease. Additionally in another 50 cases 
(25%) there was no HBV DNA level documented hence 
the patient could be either an inactive HBV carrier or 
HBeAg Neg CHB (pre-core mutation).  
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Figure 3: Distribution of study population according to 
disease phase. 
 
 
 
 
 
Treatment (Figure 3) 
Given the high proportion of patients who were 
not assessed further once HBsAg was detected, it was 
not surprising to find that most HBsAg patients in 
Malta are untreated. Even on excluding patients with 
missing data, according to the EASL guidelines, 
treatment is recommended in patients in the immune 
reactive phase (7%) as well as patients with the pre-
core mutation (10%). This study showed that only 13 
patients (6.6%) of the study population received 
treatment with Interferon-Alpha, NUCS or both. 
Prevalence of cirrhosis in HBV (Figure 4) 
It is important to determine if the patient is 
cirrhotic, since cirrhotic patients with active viral 
replication (HBV DNA positive) will require urgent 
treatment. The presence of  cirrhosis is best diagnosed 
by liver biopsy but can also be inferred from 
ultrasound findings (splenomegaly, nodular liver), a 
low platelet count or oesophageal varices at endoscopy. 
Only 15 (7.6%) patients were clearly suffering from 
cirrhosis. Of note in 32% of the study population there 
was insufficient data documented in their files to 
determine whether cirrhosis is present or not.  
 
N=197 
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 Figure 4. Prevalence of cirrhosis in HBV 
 
Discussion 
These results clearly show that HBV infection is still 
ongoing in the Maltese Islands in spite of there being an 
effective vaccine for the last 20 years. The typical HBsAg 
positive Maltese patient probably does not admit to high 
risk behaviour and health care workers should avoid 
contact with blood at all times. Unfortunately the results 
also show that HBsAg positive patients are often not 
referred for further assessment and treatment. This may be 
secondary to patient reluctance given that considerable 
stigma is still attached to the disease. Patients may also 
represent a difficult to treat group with most being 
noncompliant to follow up visits / actively abusing drugs 
etc. As most of these patients are entirely asymptomatic in 
the early phases of chronic infection there is also little 
motivation for further investigation and treatment. Health 
care providers may not be aware that major advances in 
the understanding and treatment of HBV were made in the 
last few years and that the condition has in fact become 
very satisfying to treat. All patients found to be 
HBsAg positive should be referred for specialist care 
and will require lifelong follow up. The main 
limitations of this study are that it does not determine 
prevalence of HBV in Malta since there was no 
random sampling of the general population and the 
study has all the limitations of a retrospective study. 
The authors would finally like to acknowledge and 
thank the Virology Pathology Dept, The Medical 
Records, The Blood Transfusion Dept and Detox 
Centre for their valuable contributions.  
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